High rate of discontinuations of highly active antiretroviral therapy as a result of antiretroviral intolerance in clinical practice: Missed opportunities for adherence support? [2]

AIDS

Volumn 16, Issue 7, 2002, Pages 1084-1086

  Park Wyllie, Laura Y ^a   Scalera, Alissa ^a   Tseng, Alice ^a   Rourke, Sean ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; ENFUVIRTIDE; INDINAVIR; LOPINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; TENOFOVIR;

CLINICAL PRACTICE; DRUG CAPSULE; DRUG FORMULATION; DRUG HYPERSENSITIVITY; ENTERIC COATED TABLET; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; LETTER; PATIENT COMPLIANCE; PRIORITY JOURNAL; TREATMENT FAILURE;

AGE FACTORS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; HEALTH SURVEYS; HIV INFECTIONS; HUMANS; PATIENT COMPLIANCE; PATIENT DROPOUTS; PATIENT EDUCATION; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT FAILURE;

EID: 0037013084     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200205030-00021     Document Type: Letter

References (14)

1. Reasons for modification and discontinuation of antiretrovirals: Results from a single treatment centre
2. Incidence and predictors of virologic failure to indinavir and or ritonavir in an urban health clinic
3. Effect of antiretroviral therapy on viral load, CD4 cell count, and progression to acquired immunodeficiency syndrome in a community human immunodeficiency virus-infected cohort. Swiss HIV Cohort Study
4. Outcome and predictors of failure of highly active antiretroviral therapy: One-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons
5. Predictors of optimal virological response to potent antiretroviral therapy
6. Outcome of a second-line protease inhibitor-containing regimen in patients failing or intolerant of a first highly active antiretroviral therapy
7. Reasons for discontinuation of first highly active antiretroviral therapy in a cohort of proteinase inhibitor-naive HIV-infected patients
8. Switch of protease inhibitor-containing HAART in routine clinical practice: A four-year prospective observational study
9. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients
10. Incidence of discontinuation of highly active antiretroviral combination therapy (HAART) and its determinants
11. Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued?
12. Switching HIV-1 protease inhibitor therapy: Which? when? and why?
13. Analysis of the discontinuation of protease inhibitor therapy in routine clinical practice
14. Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection